Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Bone Therapeutics   /   Forum Bone Therapeutics geopend

Aandeel BIOSENIC BRU:BIOS.BL, BE0974280126

Laatste koers (eur) Verschil Volume
0,006   0,000   (-6,56%) Dagrange 0,006 - 0,006 3.884.448   Gem. (3M) 6M

Forum Bone Therapeutics geopend

Volgen
319 Posts
Pagina: «« 1 2 3 4 5 6 ... 16 »» | Laatste | Omlaag ↓
  6. Bassie152 29 mei 2017 16:33
    Bone Therapeutics strengthens Board with the appointments of Steve Swinson and Damian Marron as Non-Executive DirectorsSenior executives with international experience in orthopaedics and cell therapy

    Gosselies, Belgium, 29 May 2017, 7am CEST - BONE THERAPEUTICS (Euronext Brussels and Paris:BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces the appointment of Steve Swinson and Damian Marron to its Board of Directors as Non-Executive Directors.

    The appointments of Steve Swinson and Damian Marron, effective 26 May 2017, complement an already strong Board of Bone Therapeutics bringing in specific public company, orthopaedic and cell therapy understanding and expertise and will provide ongoing support to the leadership team. Steve Swinson and Damian Marron will replace Jacques Reymann and Jean-Jacques Verdickt.

    Steve Swinson has served in a number of senior roles in orthopaedic medical technology and electronics companies, including general management, senior strategy, sales, marketing and commercial operation positions at Medtronic International, a global leader in medical technology. At Medtronic, he led the Spine and Biologics division for Canada and Western Europe, and was Vice President and General Manager for the international spine divison with substantial revenue responsibility. In a 30 year international business career covering Asia, US, Europe and Africa, he has also held senior positions at the diagnostic and medical departments of the blue chip engineering multinationals, General Electric and Hewlett Packard. Steve has a PhD in electrical engineering from the University of Manchester and a MBA from the University of Chicago.

    Damian Marron is an experienced life sciences executive with a successful track record of value creation through public and venture capital financing, portfolio planning and turnaround, M&A, licensing agreements and research and marketing collaborations. He has particular competencies in cell therapy, immuno-oncology and orphan diseases. Damian served most recently as Chief Executive Officer of Agalimmune and has also served as Chief Executive Officer of TxCell, a France-based specialist in personalised T-cell immunotherapies, where he led the Company's IPO on Euronext Paris. As Chief Executive Officer of Trophos, France, he helped raise EUR 34 million in financing and positioned the company for a subsequent acquisition by Roche for EUR 700 million. Damian also served as Executive Vice President, Corporate Development, for NiCox, where he supported the CEO in financing rounds raising over EUR 175 million.

    Michel Helbig de Balzac, Chairman of Bone Therapeutics, commented: "We are delighted to welcome Steve and Damian to the Board of Bone Therapeutics. Their collective track record in leadership and value creation in the healthcare sector and their industry knowledge and expertise in orthopaedic medical technology and cell therapy respectively will be a major asset to the Company. They will be a valuable sounding board to the leadership team as it focuses on advancing our innovative allogeneic cell therapy platform towards commercialization. We would like to thank Jacques Reymann and Jean-Jacques Verdickt for their many years of dedication to Bone Therapeutics and wish them the best in their well-deserved retirement."

    Commenting on his appointment, Steve Swinson said: "Bone Therapeutics leads the field in regenerative approaches to orthopaedics and bone diseases, and its allogeneic cell therapy platform has the potential to transform medicine in these areas. I'm delighted to have the opportunity to use my deep experience in orthopaedic medical technology to help support this Company as it advances its technology towards commercialization."

    Damian Marron added: "I am very excited to be joining Bone Therapeutics. I look forward to bringing my experience in strategic development and my expertise in cell therapy to support the Company as it approaches key value inflection points with its innovative allogeneic cell therapy platform."

    About Bone Therapeutics

    Bone Therapeutics is a leading cell therapy company addressing high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy products in clinical development across a number of disease areas targeting markets with large unmet medical needs and limited innovation.

    Our technology is based on a unique, proprietary approach to bone regeneration which turns undifferentiated stem cells into "osteoblastic", or bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery.

    Our primary clinical focus is ALLOB®, an allogeneic "off-the-shelf" cell therapy product derived from stem cells of healthy donors, which is in Phase II studies for the treatment of delayed-union fractures and spinal fusion. The Company also has an autologous bone cell therapy product, PREOB®, obtained from patient`s own bone marrow and currently in Phase III development for osteonecrosis and non-union fractures.

    Bone Therapeutics` cell therapy products are manufactured to the highest GMP standards and are protected by a rich IP estate covering nine patent families. Further information is available at: www.bonetherapeutics.com.

    Read more: www.nasdaq.com/press-release/bone-the...
  7. +brammeke 8 juni 2017 23:25
    Bone Therapeutics SA : completes patient recruitment for pivotal interim analysis of Phase III Osteonecrosis trial with PREOB®


    08 juni 2017 07:00
    Regulated information
    Bone Therapeutics completes patient recruitment for pivotal interim analysis of Phase III Osteonecrosis trial with PREOB ®
    Positive results could lead to further validation of Company's bone-cell therapy platform
    Results of interim data analysis expected Q3 2018
    Gosselies, Belgium, 8 June 2017, 7am CEST - BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces that it has completed the recruitment of the 44 treated patients required for the planned interim analysis of the Phase III trial for the treatment of osteonecrosis of the hip with its autologous bone cell therapy product, PREOB ® . If results from this interim analysis, based on a 12-month follow up of patients document a strong efficacy signal for PREOB ® , the study recruitment could be terminated prematurely. Results from the 12-month follow up are expected in Q3 2018.
    The interim analysis will be based on an updated clinically relevant endpoint, endorsed by the European Medicines Agency, which reflects the value added to patients and uses a composite responder analysis combining the original co-primary variables, without impacting the design and data collection of the study. This more stringent primary endpoint criterion in the revised analysis has enabled a reduction of the number of patients to be enrolled, to 118 from 130. Also, as stated in the protocol approved by the Competent Authorities in the countries where the study is being conducted, a strong efficacy signal at the interim analysis could enable the early termination of the study. The study is underway at centres in Belgium, France, Germany, the Netherlands and the United Kingdom.
    The Phase III study is a randomized, double-blind, placebo-controlled pivotal trial that aims to confirm the safety and efficacy of PREOB ® in early-stage osteonecrosis of the femoral head over a 24-month period. The patients received either a single administration of PREOB ® , or a placebo into the necrotic lesion using a core decompression procedure. Results from an earlier exploratory Phase IIB osteonecrosis study, presented at the Annual European Congress for Rheumatology (EULAR) in June 2016, demonstrated a strong and prolonged improvement in pain and function as well as a reduction in fracture risk after treatment with PREOB ® compared to standard of care.
    Osteonecrosis is a rare but severe and painful orthopaedic condition characterised by the death of bone tissue, eventually causing the bone to fracture. The most common form of osteonecrosis occurs in the hip where the disease causes femoral head collapse and joint destruction. If left untreated, the condition ultimately requires a total hip replacement but, due to the age of people affected (typically between 30 and 50) hip replacement is not an appropriate long-term solution due to the limited lifespan of prostheses.
    Thomas Lienard, CEO of Bone Therapeutics, commented: "PREOB ® has provided critical proof of concept for Bone Therapeutics in the development of its unique bone cell therapy platform. The completion of recruitment for the interim analysis in the PREOB ® Phase III osteonecrosis trial is an important step in the validation of our platform, which is now in advanced clinical development for our off-the-shelf, allogeneic product ALLOB ® . We look forward to announcing the outcome of the interim study in Q3 2018, following the completion of the twelve-month follow-up period and the potential to bring a new treatment option to patients suffering from this debilitating orphan disease."
    "We are proud to have treated the 44 patients needed for the interim analysis of the PREOB ® Phase III trial in osteonecrosis," commented Miguel Forte, Chief Medical Officer of Bone Therapeutics. "The new, robust optimised analysis we have adopted is more relevant from a patient outcome and clinical benefit perspective, compared with the initial approach and could enable us to reach an outcome with fewer patients, accelerating the progress of the study."
    About Bone Therapeutics
    Bone Therapeutics is a leading cell therapy company addressing high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy products in clinical development across a number of disease areas targeting markets with large unmet medical needs and limited innovation.
    Our technology is based on a unique, proprietary approach to bone regeneration which turns undifferentiated stem cells into "osteoblastic", or bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery.
    Our primary clinical focus is ALLOB ® , an allogeneic "off-the-shelf" cell therapy product derived from stem cells of healthy donors, which is in Phase II studies for the treatment of delayed-union fractures and spinal fusion. The Company also has an autologous bone cell therapy product, PREOB ® , obtained from patient`s own bone marrow and currently in Phase III development for osteonecrosis and non-union fractures.
    Bone Therapeutics` cell therapy products are manufactured to the highest GMP standards and are protected by a rich IP estate covering nine patent families. Further information is available at: www.bonetherapeutics.com .
  9. +brammeke 9 juni 2017 19:39
    gaat lekker. Bij tussentijdse "dip" koop ik 4 de pakketje bij.Nog steeds de "kleinste" in mijn port. Gem. nu aan 7,75.Verwacht er erg veel van, maar op dit ogenblik NOG groter "risico" dan mdxh, ablx, bcart.De "echte" doorbraak verwacht ik niet voor 2020. Bij geen uitbraak uitbraak WO 3, denk ik aan koersen 40-50euro.
    Lees meer op: beursig.com/forum/viewtopic.php?f=4&a...
  17. tony0001 13 juni 2017 10:00
    Ik zie op Bolero altijd veel kleine orders verschijnen van 10, 11 en 12 stuks aan een koers van vandaag rond de10,5 euro. Iemand een verklaring voor die kleine orders. zelf betaal ik 15 euro om een order uit te voeren. Als dit voor deze orders ook zo is, dan kun je daar toch zelden winst op maken vermoed ik? +1,5 per aandeel om te kopen en idem om te verkopen. Of zie ik dit verkeerd.
  19. +brammeke 13 juni 2017 17:54
    kanaalz.knack.be/beurs/z-beurs-1 ... 64901.htmlZie nieuwsbericht vorige week ( 08/06/2017).Laatste nieuws kort:Studie osteonecrose mag "misschien" vervroegd afgesloten worden 3de kwartaal 2018.Zal dan hun 1 ste produkt op de markt zijn.2de kwartaal 2018 zal waarschijnlijk het geld op zijn.Blijf erbij, als alles goed blijft verlopen, de echte grote doorbraak 2019-2020.
319 Posts
Pagina: «« 1 2 3 4 5 6 ... 16 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee